Daiichi Sankyo Co. Ltd. has posted results from a Phase III trial of its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban. The compound met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). Once-daily edoxaban also demonstrated significant reductions in major bleeding compared to warfarin, achieving superiority for the principal safety e...